State Street
ADVM

State Street’s Adverum Biotechnologies ADVM Stock Holding History

State Street’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-68,734
Closed -$311K – 4289
2025
Q3 		$311K Sell
68,734
-90
-0.1% -$265 ﹤0.01% 3772
2025
Q2 		$148K Sell
68,824
-295,150
-81% -$826K ﹤0.01% 3898
2025
Q1 		$1.59M Sell
363,974
-5,580
-2% -$25.1K ﹤0.01% 3323
2024
Q4 		$1.73M Sell
369,554
-62
-0% -$417 ﹤0.01% 3365
2024
Q3 		$2.59M Buy
369,616
+91,112
+33% +$662K ﹤0.01% 3235
2024
Q2 		$1.91M Buy
278,504
+213,780
+330% +$1.99M ﹤0.01% 3332
2024
Q1 		$915K Buy
64,724
+31,709
+96% +$482K ﹤0.01% 3492
2023
Q4 		$249K Hold
33,015
– – ﹤0.01% 3844
2023
Q3 		$495K Buy
33,015
+4,830
+17% +$86.7K ﹤0.01% 3665
2023
Q2 		$448K Hold
28,185
– – ﹤0.01% 3713
2023
Q1 		$202K Hold
28,185
– – ﹤0.01% 4079
2022
Q4 		$163K Hold
28,185
– – ﹤0.01% 4190
2022
Q3 		$268K Hold
28,185
– – ﹤0.01% 4013
2022
Q2 		$338K Sell
28,185
-147,565
-84% -$1.55M ﹤0.01% 3985
2022
Q1 		$2.3M Sell
175,750
-8,341
-5% -$122K ﹤0.01% 3507
2021
Q4 		$3.24M Sell
184,091
-20,671
-10% -$414K ﹤0.01% 3454
2021
Q3 		$4.44M Sell
204,762
-752,662
-79% -$19.2M ﹤0.01% 3301
2021
Q2 		$33.5M Buy
957,424
+430,059
+82% +$23.2M ﹤0.01% 2139
2021
Q1 		$52M Buy
527,365
+100,906
+24% +$12.1M ﹤0.01% 1724
2020
Q4 		$46.2M Sell
426,459
-136,280
-24% -$16.9M ﹤0.01% 1691
2020
Q3 		$58M Buy
562,739
+215,227
+62% +$32.2M ﹤0.01% 1348
2020
Q2 		$72.6M Buy
347,512
+13,303
+4% +$2.36M 0.01% 1184
2020
Q1 		$32.7M Buy
334,209
+21,932
+7% +$2.56M ﹤0.01% 1524
2019
Q4 		$36M Sell
312,277
-172,101
-36% -$15.2M ﹤0.01% 1749
2019
Q3 		$26.4M Buy
484,378
+332,776
+220% +$37.5M ﹤0.01% 1880
2019
Q2 		$18M Buy
151,602
+56,674
+60% +$4.69M ﹤0.01% 2181
2019
Q1 		$4.97M Buy
94,928
+3,451
+4% +$140K ﹤0.01% 2753
2018
Q4 		$2.88M Sell
91,477
-1,919
-2% -$78.1K ﹤0.01% 2974
2018
Q3 		$5.65M Buy
93,396
+6,146
+7% +$345K ﹤0.01% 2805
2018
Q2 		$4.63M Buy
87,250
+82,597
+1,775% +$4.97M ﹤0.01% 2898
2018
Q1 		$270K Buy
4,653
+3,262
+235% +$203K ﹤0.01% 3517
2017
Q4 		$50K Buy
+1,391
New +$45.8K ﹤0.01% 3643
2017
Q2 		– Sell
-33,217
Closed -$899K – 3699
2017
Q1 		$899K Buy
33,217
+1,090
+3% +$31K ﹤0.01% 3291
2016
Q4 		$934K Buy
32,127
+2,411
+8% +$78.8K ﹤0.01% 3289
2016
Q3 		$1.22M Buy
29,716
+302
+1% +$11.5K ﹤0.01% 3143
2016
Q2 		$929K Buy
29,414
+1,454
+5% +$65.7K ﹤0.01% 3290
2016
Q1 		$1.45M Buy
27,960
+3,241
+13% +$181K ﹤0.01% 3106
2015
Q4 		$2.35M Buy
24,719
+1,404
+6% +$123K ﹤0.01% 2934
2015
Q3 		$1.92M Buy
23,315
+2,324
+11% +$297K ﹤0.01% 3015
2015
Q2 		$3.41M Buy
20,991
+10,850
+107% +$3.66M ﹤0.01% 2837
2015
Q1 		$4.11M Buy
10,141
+2,020
+25% +$854K ﹤0.01% 2674
2014
Q4 		$4.39M Buy
8,121
+2,441
+43% +$941K ﹤0.01% 2632
2014
Q3 		$1.94M Buy
+5,680
New +$1.69M ﹤0.01% 3030

State Street's ADVM Position: Q4 2025 in Review

State Street sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 68,734 shares — an estimated $311K sold.

State Street first reported a position in ADVM in Q3 2014 and held it in 43 quarters. The position peaked at $72.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • State Street reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • State Street sold 68,734 Adverum Biotechnologies shares in Q4 2025, an estimated $311K.
  • State Street first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 43 quarters.
  • State Street's Adverum Biotechnologies position peaked at $72.6M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on State Street's 13F filing for Q4 2025, filed 13 Feb 2026.